ClinicalTrials.gg
RecruitingNCT07698145M3-EUpdated Jul 15, 2026

Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise

An interventional study of Standard Medical Care with an Obesity Management Medication and Cardiovascular Exercise Training in Obesity & Overweight, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Obesity by University of Kansas Medical Center — 9 open to participants now, 9 under way, none of them phase 3. Obesity · University of Kansas Medical Center.

Planned enrollment
7th of 29
198 · median 60
Started
2026
with 1 other
No phase
28 of 32
6 open now
Registered
31st of 32
by date

Among the 32 studies in Obesity by University of Kansas Medical Center, this one is the 7th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, and was the 31st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 32 studies in Obesity by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by University of Kansas Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether adding either cardiovascular exercise or resistance exercise to pharmacotherapy treatment for obesity improves the retention of lean mass compared to pharmacotherapy alone in adults with overweight or obesity who are prescribed pharmacotherapy for obesity treatment by their personal physician. It will also provide information about whether either form of exercise added to pharmacotherapy for obesity treatment has additional benefits on other health and fitness measurements. The main questions it aims to answer are:

  • Is there a difference in the change in total lean body mass between pharmacotherapy alone and either pharmacotherapy plus cardiovascular exercise or pharmacotherapy plus resistance exercise?
  • Is there a difference in the change in muscle mass between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in muscle quality between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in body weight between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in body composition (fat mass, fat mass distribution) between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in cardiorespiratory fitness between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in muscle strength between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in physical function between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in bone mineral density between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in bone biomarkers between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in resting blood pressure between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in energy intake between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there a difference in the change in physical activity between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?
  • Is there an effect of sex, race/ethnicity, age, menopausal status, obesity management medication type, or other demographic characteristics on the outcomes that are being measured.
  • What is the extent to which the retention of lean body mass or muscle mass mediates the effect of exercise on weight changes.

Participants will:

  • Initiate and continue throughout the study period an eligible obesity management medication that is prescribed by their healthcare provider, and to report their adherence to this medication to the investigators.
  • Participant in this study for a period of 6-8 months to complete outcome assessments that occur at baseline and at the conclusion of 6 months of the intervention period, and monitoring visits that occur at weeks 3, 6, 9, 12, 15, 18, and 21.
  • If attend 3 supervised exercise sessions per week if assigned to either the cardiovascular exercise intervention or the resistance training intervention for a period of 24 weeks.
03

Conditions studied

  • Obesity & Overweight

Keywords

  • overweight
  • obesity
  • exercise
  • physical activity
  • pharmacotherapy
  • body composition
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both males and females of all race/ethnic groups are eligible for participation in this study.
  • 18 to \<65 years of age.
  • Newly prescribed FDA-approved obesity manage medication that can include Tirzepatide, Semaglutide, or up to 4 additional next-generation obesity management medications (will receive DSMB approval prior to inclusion), approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated).
  • (BMI) of >=27.0 kg/m2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or >=30 kg/m2 without weight-related complications. We will not limit enrollment based on an upper BMI level provided that the participant meets the other eligibility requirements. However, the participant will be excluded if they exceed the weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition or the MRI that is used to assess muscle quality.
  • Ability to provide prior to participation in this study.
  • Clearance from the study physician for meeting all eligibility criteria for this study.

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes.
  • Report moderate-to-vigorous exercise for >60 min/week, and >1 day/week of structured cardiovascular or resistance exercise over the past 3 months.
  • Report sustained weight loss of >=3% in the past 3 months.
  • History of metabolic/bariatric surgery.
  • Females who are pregnant or breastfeeding or reporting a planned pregnancy during the study period.
  • Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.
  • History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.).
  • to MRI (e.g., metal implants that are not MRI safe, etc.). NOTE: Participants who are otherwise eligible other than being contraindicated for the MRI scan will be eligible and the MRI scan will not be performed as a research procedure.
  • Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
  • Resting systolic blood pressure of >=160 mmHg or resting diastolic blood pressure of >=100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for >=6 months.
  • Eating disorders that would contraindicate weight loss or physical activity.
  • Alcohol or substance abuse.
  • Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.
  • Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Standard Care with an Obesity Management Medication

    Participants will receive standard medical care from their personal physician related to their obesity management medication for a period of 6 months. Progression of this medication will be monitored as part of the participation in this study. Participants will undergo screening and baseline assessments prior to initiating the use of the medication and after a period of 6 months. Upon randomization, participants will receive a "Nutrition 101" session where dietary considerations while taking this medication will be discussed. We will also have a brief contact (weeks 3, 6, 9, 12, 15, 18, and 21) with the participant to monitor changes in weight, blood pressure, health status, and medication adherence and use (including the dose of the obesity management medication that they have been prescribed). Participants will be instructed to maintain their current level of physical activity throughout the 6-month study period.

    Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Nutrition Counseling

  • Experimental
    Standard Care with an Obesity Management Medication Plus Cardiovascular Exercise Training

    Participants will receive the same standard of care as described for the "Standard Care with an Obesity Management Medication" condition; however, participants will also engage in supervised cardiovascular exercise training. This will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, we will allow for alternative forms of cardiovascular exercise (upright or recumbent cycling, elliptical, etc.) to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.

    Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Cardiovascular Exercise Training · Behavioral: Nutrition Counseling

  • Experimental
    Standard Care with an Obesity Management Medication Plus Resistance Exercise Training

    Participants will receive the same standard of care as described for the "Standard Care with an Obesity Management Medication" condition; however, participants will also engage in supervised resistance exercise training. This will occur 3 days per week and involve 9 different exercises. Each exercise will progress to 3 sets with a rest period of 60 to 90 seconds between each set. Warm-up sets will include 10 repetitions, and all remaining sets will perform repetitions until volitional fatigue. Heart rate will be monitored throughout these exercise sessions.

    Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Resistance Exercise Training · Behavioral: Nutrition Counseling

Interventions

  • OtherStandard Medical Care with an Obesity Management Medication

    Participant will receive standard medical care that includes the prescription and titration of a study eligible obesity management medication.

  • BehavioralCardiovascular Exercise Training

    Participant will receive supervised cardiovascular exercise training on 3 days per week for a period of 6 months.

  • BehavioralResistance Exercise Training

    Participant will receive supervised resistance exercise training on 3 days per week for a period of 6 months.

  • BehavioralNutrition Counseling

    Participant will receive brief nutrition counseling specific to obesity managment medications after randomization for this study.

06

What researchers measure

Primary outcomes

  1. Lean body mass

    Lean Body Mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

Secondary outcomes

  1. Muscle Mass

    Muscle Mass (kg) will be assessed using the deuterated creatine (D3Cr) dilution method.

    Time frame: 0 and 6 months

  2. Muscle Quality

    Muscle quality will be assessed using magnetic resonance imaging (MRI) of the mid-thigh.

    Time frame: 0 and 6 months

  3. Body Weight

    Body weight will be assessed in duplicate using a calibrated digital scale to the nearest 0.1 kg.

    Time frame: 0 months, week 6, week 12, week 18, 6 months

  4. Body Mass Index

    Measurements of weight and height will be used to compute BMI (kg/m2).

    Time frame: 0 months, week 6, week 12, week 18, 6 months

  5. Percent body fat

    Percent body fat will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  6. Body Fat Mass

    Body fat mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  7. Bone mineral content

    Bone mineral content (grams) will be assessed using total body, femur, and spine scans from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  8. Bone mineral density

    Bone mineral density (g/cm2) will be assessed using total body, femur, and spine scans from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  9. Bone Biomarkers

    Bone biomarkers will be assessed from blood samples collected using venipuncture.

    Time frame: 0 and 6 months

  10. Waist Circumference

    Circumference measures of the waist will be taken horizontally at both the iliac crest and the umbilicus.

    Time frame: 0 and 6 months

  11. Hip Circumference

    Circumference measures of the hip will be taken horizontally at the widest observed portion of the buttocks.

    Time frame: 0 and 6 months

  12. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be represented as milliliters of oxygen consumed per kilogram of body weight per minute (ml/kg/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.

    Time frame: 0 and 6 months

  13. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be represented as total liters of oxygen consumed per minute (L/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.

    Time frame: 0 and 6 months

  14. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be the duration measured in minutes to achieve 85% of age-predicted maximal heart rate during a submaximal graded exercise test performed on a treadmill or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.

    Time frame: 0 and 6 months

  15. Muscle Strength

    Muscular strength will be measured from an isometric leg extension performed on a dynamometer.

    Time frame: 0 and 6 months

  16. Physical Function

    Physical function will be measured using the Short Physical Performance Protocol (SPPB) that includes balance, gait speed, and chair stands).

    Time frame: 0 and 6 months

  17. Muscle Power

    Muscle Power is measured using the Margaria Power Stair Climb Task that requires the participant to walk up a standardized flight of stair, with the score being the time it takes to walk from the 3rd step to the 9th step. A faster time at a given body mass indicates a greater level of muscle power.

    Time frame: 0 and 6 months

  18. Health-Related Quality of Life

    Health-related quality of life is assessed with a standardized questionnaire. This questionnaire consists of 8 scales (physical functioning, role limitations caused by health problems, role limitation caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, general health perceptions) with each scale score between 0-100. This also consists of 2 subscales (physical and mental health) with these being scored as the average of the scores from the scales that are factored into each measure. This also provides an overall score, which is the average of the scores for each of the 8 scales. A higher score on a scale or subscale indicates a higher health-related quality of life.

    Time frame: 0 and 6 months

  19. Energy Intake (Dietary Intake)

    Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using the Diet History Questionnaire (DHQ) developed by NCI. A higher score represents more calories eaten.

    Time frame: 0 months, week 6, week 12, week 18, 6 months

  20. Energy Intake (Dietary Intake)

    Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using a 3-day dietary recall (2 weekdays and 1 weekend day). A higher score represents more calories eaten.

    Time frame: 0 months, week 6, week 12, week 18, 6 months

  21. Physical Activity

    Physical activity will be measured using the Physical Activity and Exercise Questionnaire. A higher score represents more physical activity expressed as minutes per week or calories of energy expenditure per week.

    Time frame: 0 and 6 months

  22. Physical Activity

    Physical activity will be measured using the Global Physical Activity Questionnaire (GPAQ). A higher score represents more physical activity expressed as minutes per week or calories of energy expenditure per week.

    Time frame: 0 and 6 months

  23. Physical Activity

    Physical activity will be measured Garmin wrist worn activity tracker that will be provided to each participant to wear throughout the entire 6 month intervention period. A higher score represents more physical activity.

    Time frame: 0 and 6 months

Other outcomes

  1. Medication Reporting

    A questionnaire developed specifically for this study will be used to assess medication history and use of prescribed obesity management medications. The data collected include the type of medication, dose of medication, and frequency that the medication is taken, and what condition the medication is indicated to treat.

    Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21

  2. Obesity Management Medication Adherence

    A questionnaire developed specifically for this study will be used to assess adherence to the prescribed obesity management medications. The data collected include the type of medication, dose of medication, and frequency that the medication is taken.

    Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21

  3. Demographic Characteristics

    A questionnaire developed specifically for this study will be used to assessment demographic characteristics (age, sex, race, etc.).

    Time frame: 0 months

  4. Lifestyle and Health History

    A questionnaire developed specifically for this study that is conducted as an interview will be used to assess lifestyle and health factors to describe the sample for this study. The score is either "yes" or "no" identifying the presences of a lifestyle or health factor.

    Time frame: 0 months (prior to randomization)

  5. Adverse and Serious Adverse Events

    Participants will be queried using a survey developed specifically for this study will be used to assess for adverse events and serious adverse events.

    Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21 and at other times when reported by the participant

07

Study locations

1 of 1 sites recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • John M. Jakicic, PhD · Contactjjakicic@kumc.edu · 913-588-9078
    • Renee J. Rogers, PhD · Contactrrogers10@kumc.edu · 913-588-8580
    • John M. Jakicic, PhD · Principal investigator
    • Renee J. Rogers, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The summary data for each of the study outcomes and other additional demographic characteristics will be made available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be made available no later than the time of an associated publication of study outcomes or at the end of the performance period, whichever comes first. The data provided to the repository will be available indefinitely while that repository continues to exist.

Access criteria: The information included with the IPD will be made available to appropriate individuals only after the requester confirms their willingness to comply with an appropriate "Data Use Agreement" that complies with NIH policies, the policies of the institution where the study has been conducted, and the elements of informed consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Mar 2030, 44 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 13, 2026
StartEst.
Jul 31, 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698145
Responsible party
John M. Jakicic, PhD (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Jul 13, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jul 15, 2026

Study contacts

John M. Jakicic, PhD
Contact
jjakicic@kumc.edu
913-588-9078
Renee J. Rogers, PhD
Contact
rrogers10@kumc.edu
913-588-8580
John M. Jakicic, PhD
principal investigator · University of Kansas Medical Center
Renee J. Rogers, PhD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion